Delhi HC Issues Contempt Notice to CDSCO Over Weight-Loss Drug Regulation Delay

The Delhi High Court’s decision to issue a contempt notice to the Central Drugs Standard Control Organisation (CDSCO) represents a critical juncture in India’s pharmaceutical regulatory landscape. Presided over by Justice Sachin Datta, the court’s move follows an alleged failure by the CDSCO to comply with a prior judicial mandate. That mandate required the regulator to investigate the safety and regulatory frameworks surrounding the off-label use of diabetes medications—specifically those increasingly popular for weight management. This development is not merely a procedural dispute; it is a direct challenge to the perceived inertia of India’s primary drug regulator in the face of a global pharmacological phenomenon.

The drugs in question, primarily GLP-1 receptor agonists, have seen an unprecedented surge in demand worldwide. While originally approved for the treatment of Type 2 diabetes, their efficacy in inducing significant weight loss has led to widespread off-label use, often fueled by social media trends and celebrity endorsements. In India, where the regulatory environment for off-label marketing is historically less stringent than in the US or EU, the court’s intervention signals a shift toward proactive judicial oversight. The core of the legal grievance lies in the CDSCO’s delay in establishing clear safety protocols or warnings for non-diabetic patients using these potent medications.

“

The Delhi High Court’s decision to issue a contempt notice to the Central Drugs Standard Control Organisation (CDSCO) represents a critical juncture in India’s pharmaceutical regulatory landscape.

From a RegTech and legal compliance perspective, this case underscores the increasing risks of administrative non-compliance. For pharmaceutical companies operating in India, the contempt notice suggests that the "wait and see" approach often adopted by regulators may no longer be a viable shield against legal liability. If the court forces the CDSCO’s hand, we can expect a rapid rollout of new clinical trial requirements or restrictive labeling mandates. Legal departments within the life sciences sector must now prepare for a more aggressive regulatory posture, as the CDSCO will likely seek to demonstrate its diligence to the court by tightening oversight on distribution and marketing.